**Core tip:** Unlike previous studies conducted more than a decade ago, most current studies no longer suggest that periampullary diverticulum (PAD) significantly increases the difficulty of cannulation. However, we found that different clinical types of PAD may affect the difficulty and even success of endoscopic retrograde cholangiopancreatography (ERCP) cannulation. Furthermore, existing PAD classifications have limited clinical guidance value. We proposed a new PAD classification method (Li-Tanaka classification) in 2012 based on the number of PADs and their anatomical relationship with the major papilla, and we conducted a retrospective study to evaluate the clinical value of the Li-Tanaka PAD classification for ERCP cannulation. Our study showed that the Li-Tanaka classification has good clinical significance for ERCP cannulation.

INTRODUCTION
============

Diverticulum is a common intestinal anatomical variation. A periampullary diverticulum (PAD) is defined as a duodenal depressed lesion of more than 5 mm with an intact mucosa within a radius of 2.5 cm of the major papilla. The clinical discovery rates of PAD vary from 6% to 31.7%\[[@B1]-[@B3],[@B23]\], and the prevalence of PAD increases with age. Our previous study\[[@B4]\] found that PAD may increase the incidence of choledocholithiasis and could be a potential risk factor for recurrent choledocholithiasis, especially after cholecystectomy. Previous studies have mainly proposed that PAD may increase the difficulty of endoscopic retrograde cholangiopancreatography (ERCP) cannulation\[[@B5]\]. However, many current studies no longer suggest that PAD significantly increases the difficulty of cannulation\[[@B2],[@B6],[@B7]\]. In clinical practice, we found that the effect of PAD on ERCP cannulation was related to the characteristics of the diverticulum.

Previously, two classifications of PAD based on the characteristics of the diverticulum were used. In 1998, Lobo et al\[[@B5]\] first divided PAD into two types: Intradiverticular papilla (IDP) and juxtapapillary diverticulum (JPD). In 2006, Boix et al\[[@B2]\] identified three types of PAD, and types I and II were further divided into four subtypes. However, the clinical significance of the two current PAD classifications for cannulation is limited.

Based on the number of PADs and their anatomical relationship with the major papilla, we worked with the Kyoto Second Red Cross Hospital to propose a new PAD classification method (Li-Tanaka classification) in 2012, and conducted a retrospective study to evaluate the clinical value of the Li-Tanaka PAD classification method for ERCP cannulation.

MATERIALS AND METHODS
=====================

Definition
----------

The Lobo classification\[[@B5]\] categorizes PAD as IDP and JPD. In IDP, the major papilla is located in a diverticulum, while in JPD, the papilla is outside the duodenal diverticulum (Figure [1A](#F1){ref-type="fig"}). The Boix classification\[[@B2]\] includes three types of PAD, of which types I and II are divided into four subtypes: Type I: The papilla is located inside the diverticulum (Ia: Up; Ib: Left; Ic: Down; Id: Right); type II: The papilla is located in the margin of the diverticulum (IIa: Apical left margin; IIb: Apical right margin; IIc: Center left or right margin; IId: Between two diverticula); and type III: The papilla is located near the diverticulum (Figure [1B](#F1){ref-type="fig"}). According to the number of diverticula and their anatomical relationship with the major papilla, we divided PAD into four types and then further divided types II and IV into two subtypes in terms of the distance from the major papilla to the edge of the diverticulum. In type I, the papilla is located inside the diverticulum and is not adjacent to the margin; in type II, the papilla is located in the margin of the diverticulum (type IIa, inside of the margin; type IIb, outside of the margin, \< 1 cm); in type III, the papilla is located outside of the margin, ≥ 1 cm; and in type IV, the papilla is located in the margin of the diverticulum and ≥ 2 diverticula are present (type IVa: The papilla is located outside the margins of at least one diverticulum, \< 1 cm; type IVb: The papilla is located outside the margins of all of the diverticula, ≥ 1 cm) (Figure [2](#F2){ref-type="fig"}).

![Lobo classification and Boix classification of periampullary diverticulum. A: Lobo classification of periampullary diverticulum; B: Boix classification of periampullary diverticulum. Type I: The papilla is located inside of the diverticulum (Ia: Up; Ib: Left, Ic: Down; Id: Right); type II: The papilla is located in the margin of the diverticulum (IIa: Apical left margin; IIb: Apical right margin; IIc: Center left or right margin; IId: Between 2 diverticula); type III: The papilla is located near the diverticulum. IDP: Intradiverticular papilla; JPD: Juxtapapillary diverticula.](WJG-26-2403-g001){#F1}

![Li-Tanaka classification of periampullary diverticulum. Type I: The papilla is located inside the diverticulum and not adjacent to the margin; type II: The papilla is located in the margin of the diverticulum (type IIa: Inside of the margin; type IIb: Outside of the margin, \< 1 cm); type III: The papilla is located outside the margin, ≥ 1 cm; type IV: The papilla is located in the margin of the diverticulum, ≥ 2 diverticula (type IVa: The papilla is located outside the margins of at least one diverticulum, \< 1 cm; type IVb: The papilla is located outside the margins of all the diverticula, ≥ 1 cm).](WJG-26-2403-g002){#F2}

According to the most current international consensus recommendations of the American Society for Gastrointestinal Endoscopy on difficult biliary access in 2017\[[@B8]\], procedures that satisfy one or more of the following conditions are regarded as difficult cannulation: (1) Failure of selective bile duct cannulation by the standard ERCP technique within 10 min; (2) More than 5 cannulation attempts; or (3) Failure to gain access to the major papilla.

Patient recruitment
-------------------

A total of 4994 consecutive patients who underwent ERCP from January 2012 to December 2017 at the First Hospital of Lanzhou University were retrospectively analyzed. Written informed consent was obtained from the patients before the procedure, and this study was approved by the institutional ethics committee at our hospital. A total of 1430 cases were excluded based on the following exclusion criteria: Patients with a history of ERCP or Billroth II anastomosis and patients under 18 years of age. These patients were excluded because these factors may directly affect the observation of diverticula and make ERCP cannulation extremely easy or difficult. Ultimately, 3564 patients aged 18 years or above with native papillae were included (Figure [3](#F3){ref-type="fig"}).

![Flow chart (Li-Tanaka classification). PAD: Periampullary diverticulum; ERCP: Endoscopic retrograde cholangiopancreatography.](WJG-26-2403-g003){#F3}

ERCP procedure
--------------

Hepatopancreatobiliary diseases and indications for ERCP were confirmed by laboratory and imaging examinations, including abdominal ultrasound, computed tomography, and magnetic resonance cholangiopancreatography. Patients were placed in the left lateral position before nontracheal intubation and general anesthesia, and a duodenoscope (JF-240, TJF-240, TJF-260 or CV-290, Olympus, Japan) was used to complete the ERCP procedure. The size, number, shape, and specific type of PAD for each classification method were noted before cannulation.

Then, major papillary cannulation was routinely performed using a sphincterotome. If the cannulation was difficult, double-wire, precut, and other techniques were used to assist cannulation. After successful cannulation, all ERCP procedures, including cholangiography, endoscopic sphincterotomy (EST), endoscopic papillary balloon dilatation (EPBD), mechanical lithotripsy, endoscopic retrograde biliary drainage, and endoscopic retrograde pancreatic drainage, were performed selectively as required. If the cannulation failed, the patient was rescheduled for ERCP or surgery.

Statistical analysis
--------------------

All clinical values are presented as the mean and standard deviation for continuous variables and counts and percentages for dichotomous variables. Global tests for quality were evaluated using analysis of variance (ANOVA), the Kruskal-Wallis test, the Pearson chi-square test, and Fisher's exact test, as appropriate. For variables in which a significant effect of global test (*P* \< 0.05) was identified, multiple comparisons were performed among the different types of PAD by Bonferroni correction, in which an α of 0.05 was adjusted to 0.017 and 0.008 for three and four groups, respectively. Multivariable-adjusted logistic models were used to estimate the odds ratio (OR) of PAD for difficult and successful cannulation. All models were adjusted for age and sex, and the results are presented as ORs with 95% confidence intervals (CIs). *P* values less than 0.05 were considered to indicate significance. All analyses were conducted using STATA 14 (Stata Corp, College Station, TX, United States).

RESULTS
=======

Baseline clinical characteristics
---------------------------------

Of the 3564 patients enrolled, 967 (27.13%) were in the PAD group, and 2597 (72.87%) were in the non-PAD group. Compared to those in the non-PAD group, the patients in the PAD group had a greater average age (65 ± 13 *vs* 58 ± 16, *P* \< 0.001), comprised a greater proportion of males (53.5% *vs* 48.1%, *P* = 0.004), had a higher incidence of common bile duct stones (85.1% *vs* 71.1%) and acute cholangitis (17.7% *vs* 11.2%), and had a lower concurrency of malignant biliary stricture (5.2% *vs* 13.8%) and acute pancreatitis (5.6% *vs* 9.6%) (*P* \< 0.001) (Table [1](#T1){ref-type="table"}). The baseline clinical characteristics of different types of PAD patients among the three classifications are presented in Table [2](#T2){ref-type="table"}.

###### 

Baseline clinical characteristics of the periampullary diverticulum and non- periampullary diverticulum groups

                                **Non-PAD group (*n* = 2597)**   **PAD group (*n* = 967)**   ***P* value**
  ----------------------------- -------------------------------- --------------------------- ---------------
  Age, mean ± SD                58 ± 16                          65 ± 13                     \< 0.001
  Sex, *n* (%)                                                                               0.004
  Male                          1248 (48.1)                      517 (53.5)                  
  Female                        1349 (51.9)                      450 (46.5)                  
  History of cholecystectomy    909 (35.0)                       356 (36.8)                  0.32
  Gallbladder stones            1001 (38.5)                      369 (38.2)                  0.83
  Indications, *n* (%)                                                                       
  Common bile duct stones       1846 (71.1)                      823 (85.1)                  \< 0.001
  Acute cholangitis             291 (11.2)                       171 (17.7)                  \< 0.001
  Malignant biliary stricture   359 (13.8)                       50 (5.2)                    \< 0.001
  Benign biliary stricture      101 (3.9)                        33 (3.4)                    0.51
  Acute pancreatitis            248 (9.6)                        54 (5.6)                    \< 0.001
  Pancreatic duct stones        18 (0.7)                         4 (0.4)                     0.35
  Comorbidity, *n* (%)                                                                       
  Hypertension                  536 (20.6)                       239 (24.7)                  0.009
  Diabetes                      212 (8.2)                        100 (10.3)                  0.04
  Coronary disease              67 (2.6)                         29 (3.0)                    0.49
  Virus hepatitis               140 (5.4)                        31 (3.2)                    0.007

PAD: Periampullary diverticulum.

###### 

Baseline clinical characteristics of different types of periampullary diverticulum patients in the three classification systems

                                **Lobo classification, 1998**   **Boix classification, 2006**                **Li-Tanaka classification, 2012**                                                                                                 
  ----------------------------- ------------------------------- -------------------------------------------- ------------------------------------ ------------ ------------------------------------------- ----------- ------------ ----------- -------------------------------------------
  Total                         65                              902                                          306                                  556          105                                         65          655          105         142
  Age, mean ± SD                65 ± 11                         65 ± 14                                      64 ± 13                              65 ± 13      65 ± 15                                     65 ± 11     64 ± 14      65 ± 15     66 ± 12
  Sex, *n* (%)                                                                                                                                                                                                                                  
  Male                          32 (49.2)                       485 (53.8)                                   167 (54.6)                           293 (52.7)   57 (54.3)                                   32 (49.2)   358 (54.7)   57 (54.3)   70 (49.3)
  Female                        33 (50.8)                       417 (46.2)                                   139 (45.4)                           263 (47.3)   48 (45.7)                                   33 (50.8)   297 (45.3)   48 (45.7)   72 (50.7)
  History of cholecystectomy    15 (23.1)                       341 (37.8)[a](#T2FN1){ref-type="table-fn"}   111 (36.3)                           221 (39.8)   24 (22.9)[a](#T2FN1){ref-type="table-fn"}   15 (23.1)   263 (40.2)   24 (22.9)   54 (38.0)[a](#T2FN1){ref-type="table-fn"}
  Gallbladder stones            28 (43.1)                       341 (37.8)                                   117 (38.2)                           215 (38.7)   37 (35.2)                                   28 (43.1)   249 (38.0)   37 (35.2)   55 (38.7)
  Indications, *n* (%)                                                                                                                                                                                                                          
  Common bile duct stones       53 (81.5)                       770 (85.4)                                   265 (86.6)                           471 (84.7)   87 (82.9)                                   53 (81.5)   561 (85.7)   87 (82.9)   122 (85.9)
  Acute cholangitis             11 (16.9)                       160 (17.7)                                   61 (19.9)                            96 (17.3)    14 (13.3)                                   11 (16.9)   119 (18.2)   14 (13.3)   27 (19.0)
  Malignant biliary stricture   2 (3.1)                         48 (5.3)                                     13 (4.3)                             28 (5.0)     9 (8.6)                                     2 (3.1)     30 (4.6)     9 (8.6)     9 (6.3)
  Benign biliary stricture      1 (1.5)                         32 (3.6)                                     8 (2.6)                              22 (4.0)     3 (2.9)                                     1 (1.5)     26 (4.0)     3 (2.9)     3 (2.1)
  Acute pancreatitis            5 (7.7)                         49 (5.4)                                     25 (8.2)                             26 (4.7)     3 (2.9)[a](#T2FN1){ref-type="table-fn"}     5 (7.7)     42 (6.4)     3 (2.9)     4 (2.8)
  Pancreatic duct stones        0                               4 (0.4)                                      2 (0.7)                              2 (0.4)      0                                           0           4 (0.6)      0           0
  Comorbidity, *n* (%)                                                                                                                                                                                                                          
  Hypertension                  19 (29.2)                       220 (24.4)                                   77 (25.2)                            134 (24.1)   28 (26.7)                                   19 (29.2)   159 (24.3)   28 (26.7)   33 (23.2)
  Diabetes                      11 (16.9)                       89 (9.9)                                     34 (11.1)                            54 (9.7)     12 (11.4)                                   11 (16.9)   66 (10.1)    12 (11.4)   11 (7.8)
  Coronary disease              5 (7.7)                         24 (2.7)[a](#T2FN1){ref-type="table-fn"}     10 (3.3)                             18 (3.2)     1 (1.0)                                     5 (7.7)     16 (2.4)     1 (1.0)     7 (4.9)[a](#T2FN1){ref-type="table-fn"}
  Virus hepatitis               2 (3.1)                         29 (3.2)                                     9 (2.9)                              17 (3.1)     5 (4.8)                                     2 (3.1)     17 (2.6)     5 (4.8)     7 (4.9)

*P* \< 0.05. IDP: Intradiverticular papilla; JPD: Juxtapapillary diverticula.

Lobo classification
-------------------

For the Lobo classification, the difficult cannulation rate for IDP was higher than that for JPD (23.1% *vs* 10.3%, *P* = 0.002), and the success rate of cannulation was lower for IDP than for JPD (90.8% *vs* 99.1%, *P* \< 0.001) (Table [3](#T3){ref-type="table"}).

###### 

Diagnosis, procedures, and post-procedure complications for different types of periampullary diverticulum in three classification systems

                            **Lobo classification, 1998**   **Boix classification, 2006**   **Li-Tanaka classification, 2012**                                                                                                                                                                                                        
  ------------------------- ------------------------------- ------------------------------- ------------------------------------ ------------ -------------------------------------------- ------------ ---------- ----------- -------------------------------------------- ------------ -------------------------------------------- ----------
  Total                     65 (6.7)                        902 (93.3)                                                           306 (31.6)   556 (57.5)                                   105 (10.9)              65 (6.7)    655 (67.7)                                   105 (10.9)   142 (14.7)                                   
  Diameter of CBD (mm)      14 ± 4                          14 ± 5                          0.33                                 14 ± 5       15 ± 5                                       14 ± 6       0.37       14 ± 4      14 ± 5                                       14 ± 6       15 ± 5                                       0.56
  Max. size of PAD (mm)     19 ± 8                          13 ± 7                          \< 0.001                             15 ± 8       13 ± 7                                       11 ± 7       \< 0.001   19 ± 8      13 ± 7                                       11 ± 7       14 ± 9                                       \< 0.001
  ≤ 10                      11 (16.9)                       531 (58.9)                                                           146 (47.7)   325 (58.5)                                   71 (67.6)               11 (16.9)   384 (58.6)                                   71 (67.6)    76 (53.5)                                    
  10-20                     38 (58.5)                       287 (31.8)                                                           118 (38.6)   182 (32.7)                                   25 (23.8)               38 (58.5)   217 (33.1)                                   25 (23.8)    45 (31.7)                                    
  \> 20                     16 (24.6)                       84 (9.3)                                                             42 (13.7)    49 (8.8)                                     9 (8.6)                 16 (24.6)   54 (8.2)                                     9 (8.6)      21 (14.8)                                    
  CBD stones                51 (86.4)                       765 (85.6)                      0.85                                 262 (87.9)   470 (85.0)                                   84 (82.4)    0.31       51 (86.4)   559 (85.9)                                   84 (82.4)    122 (86.5)                                   0.79
  Max diameter (mm)         13 ± 5                          12 ± 7                          0.23                                 12 ± 6       13 ± 7                                       12 ± 6       0.26       13 ± 5      12 ± 6                                       12 ± 6       13 ± 8                                       0.58
  Multiple stone            19 (37.3)                       353 (46.1)                      0.22                                 115 (43.9)   224 (47.7)                                   33 (39.3)    0.29       19 (37.3)   258 (46.2)                                   33 (39.3)    62 (50.8)                                    0.24
  Difficult stone removal   16 (31.4)                       273 (35.7)                      0.53                                 96 (36.6)    159 (33.8)                                   34 (40.5)    0.44       16 (31.4)   195 (34.9)                                   34 (40.5)    44 (36.1)                                    0.71
  Mechanical lithotripsy    4 (6.2)                         35 (3.9)                        0.33                                 21 (6.9)     16 (2.9)                                     2 (1.9)      0.008      4 (6.2)     31 (4.7)                                     2 (1.9)      2 (1.4)                                      0.13
  Retained stones           3 (5.9)                         59 (7.7)                        0.79                                 20 (7.6)     34 (7.2)                                     8 (9.5)      0.77       3 (5.9)     38 (6.8)                                     8 (9.5)      13 (10.7)                                    0.42
  Guide wire in PD          6 (9.2)                         86 (9.5)                        0.94                                 30 (9.8)     48 (8.6)                                     14 (13.3)    0.32       6 (9.2)     66 (10.1)                                    14 (13.3)    6 (4.2)                                      0.08
  ERPD                      1 (1.5)                         45 (5.0)                        0.36                                 11 (3.6)     31 (5.6)                                     4 (3.8)      0.38       1 (1.5)     36 (5.5)                                     4 (3.8)      5 (3.5)                                      0.50
  Operative time (min)      44 ± 21                         41 ± 18                         0.35                                 41 ± 18      41 ± 17                                      43 ± 21      0.81       44 ± 21     41 ± 17                                      43 ± 21      39 ± 17                                      0.48
  Difficult cannulation     15 (23.1)                       93 (10.3)                       0.002                                38 (12.4)    57 (10.3)                                    13 (12.4)    0.57       15 (23.1)   68 (10.4)                                    13 (12.4)    12 (8.5)                                     0.01
  Successful cannulation    59 (90.8)                       894 (99.1)                      \< 0.001                             298 (97.4)   553 (99.5)[a](#T3FN1){ref-type="table-fn"}   102 (97.1)   0.02       59 (90.8)   651 (99.4)[b](#T3FN2){ref-type="table-fn"}   102 (97.1)   141 (99.3)[b](#T3FN2){ref-type="table-fn"}   \< 0.001
  Adverse events            8 (12.3)                        79 (8.8)                        0.33                                 26 (8.5)     48 (8.6)                                     13 (12.4)    0.44       8 (12.3)    57 (8.7)                                     13 (12.4)    9 (6.3)                                      0.30
  Post-ERCP pancreatitis    5 (7.7)                         53 (5.9)                        0.58                                 19 (6.2)     29 (5.2)                                     10 (9.5)     0.23       5 (7.7)     38 (5.8)                                     10 (9.5)     5 (3.5)                                      0.24
  Acute cholangitis         2 (3.1)                         25 (2.8)                        0.70                                 6 (2.0)      18 (3.2)                                     3 (2.9)      0.55       2 (3.1)     18 (2.8)                                     3 (2.9)      4 (2.8)                                      0.98
  Perforation               1 (1.5)                         1 (0.1)                         0.13                                 1 (0.3)      1 (0.2)                                      0 (0.0)      1.00       1 (1.5)     1 (0.2)                                      0 (0.0)      0 (0.0)                                      0.20

For Boix classification, *P* = 0.017 with Bonferroni adjustment. For Li-Tanaka classification, *P* = 0.008 with Bonferroni adjustment. Successful cannulation: Boix: Type II *vs* type I,

*P* \< 0.05; Li-Tanaka classification: Type II *vs* type I,

*P* \< 0.01, type IV *vs* type I, ^b^*P* \< 0.01. CBD: Common bile duct; PAD: Periampullary diverticulum; ERCP: Endoscopic retrograde cho-langiopancreatography; ERPD: Endoscopic retrograde pancreatic drainage; PD: Pancreatic duct.

Boix classification
-------------------

For the Boix classification, no significant difference in the rate of difficult cannulation was observed (*P* = 0.57), while the successful cannulation rate of type II PAD was highest (99.5% *vs* 97.4% in type I and 97.1% in type III, *P* = 0.02) (Table [3](#T3){ref-type="table"}).

Li-Tanaka classification
------------------------

For the Li-Tanaka classification, type I PAD had the highest difficult cannulation rate (23.1% *vs* 10.4% in type II, 12.4% in type III, and 8.5% in type IV, *P* = 0.01), and type II PAD had the highest successful cannulation rate (99.4% *vs* 90.8% in type I, 97.1% in type III, and 99.3% in type IV, *P* \< 0.001). No significant difference in terms of procedure-related complications such as post-ERCP pancreatitis (PEP), acute cholangitis, and perforation were observed among the groups for all three classifications (Table [3](#T3){ref-type="table"}).

Cannulation for different types of periampullary diverticulum in the three classification groups
------------------------------------------------------------------------------------------------

Overall, compared to the non-PAD group, all the patients in the PAD group did not exhibit increased cannulation difficulty (OR = 0.86, 95%CI: 0.68-1.09, *P* = 0.21), and the success rate of cannulation was higher (OR = 1.87, 95%CI: 1.04-3.37, *P* = 0.037). For the Li-Tanaka classification, the cannulation difficulty for type I PAD was higher than that in the non-PAD group (OR = 2.04, 95%CI: 1.13-3.68, *P* = 0.004), and the successful cannulation rate for type I PAD was lower than that in the non-PAD group (OR = 0.27, 95%CI: 0.11-0.66, *P* \< 0.001). Moreover, the successful cannulation rate for type II PAD was higher than that of the non-PAD group (OR = 4.44, 95%CI: 1.61-12.29, *P* \< 0.01) (Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}).

###### 

Difficult cannulation for different types of periampullary diverticulum in the three classification groups compared with the non- periampullary diverticulum group

  **Variable**                   ***n*/*N* (%)**   **Difficult cannulation**   
  ------------------------------ ----------------- --------------------------- -------
  **Total**                                                                    
  Non-PAD                        317/2597 (12.2)   Ref                         
  PAD                            108/967 (11.2)    0.86 (0.68-1.09)            0.21
  **Lobo classification**                                                      
  Non-PAD                        317/2597 (12.2)   Ref                         
  IDP                            15/65 (23.1)      2.04 (1.13-3.68)            0.006
  JPD                            93/902 (10.3)     0.79 (0.61-1.01)            0.001
  **Boix classification**                                                      
  Non-PAD                        317/2597 (12.2)   Ref                         
  I                              38/306 (12.4)     0.98 (0.68-1.40)            0.73
  II                             57/556 (10.3)     0.78 (0.58-1.05)            0.21
  III                            13/105 (12.4)     0.97 (0.53-1.75)            0.85
  **Li-Tanaka classification**                                                 
  Non-PAD                        317/2597 (12.2)   Ref                         
  I                              15/65 (23.1)      2.04 (1.13-3.68)            0.004
  II                             68/655 (10.4)     0.80 (0.60-1.06)            0.13
  III                            13/105 (12.4)     0.97 (0.53-1.75)            0.91
  IV                             12/142 (8.5)      0.62 (0.34-1.13)            0.06

Adjusted for age and sex. PAD: Periampullary diverticulum; IDP: Intradiverticular papilla; JPD: Juxtapapillary diverticula; OR: Odds ratio; CI: Confidence interval.

###### 

Successful cannulation for different types of periampullary diverticulum in the three classification groups compared with the non- periampullary diverticulum group

  **Variable**                   ***n*/*N* (%)**    **Successful cannulation**   
  ------------------------------ ------------------ ---------------------------- ----------
  **Total**                                                                      
  Non-PAD                        2531/2597 (97.5)   Ref                          
  PAD                            953/967 (98.6)     1.87 (1.04-3.37)             0.037
  **Lobo classification**                                                        
  Non-PAD                        2531/2597 (97.5)   Ref                          
  IDP                            59/65 (90.8)       0.27 (0.11-0.66)             \< 0.001
  JPD                            894/902 (99.1)     3.07 (1.46-6.46)             \< 0.001
  **Boix classification**                                                        
  Non-PAD                        2531/2597 (97.5)   Ref                          
  I                              298/306 (97.4)     1.02 (0.48-2.15)             0.27
  II                             553/556 (99.5)     5.09 (1.59-16.30)            0.009
  III                            102/105 (97.1)     0.94 (0.29-3.04)             0.33
  **Li-Tanaka classification**                                                   
  Non-PAD                        2531/2597 (97.5)   Ref                          
  I                              59/65 (90.8)       0.27 (0.11-0.66)             \< 0.001
  II                             651/655 (99.4)     4.44 (1.61-12.29)            0.01
  III                            102/105 (97.1)     0.94 (0.29-3.04)             0.49
  IV                             141/142 (99.3)     3.97 (0.55-28.95)            0.19

Adjusted for age and sex. PAD: Periampullary diverticulum; IDP: Intradiverticular papilla; JPD: Juxtapapillary diverticula; OR: Odds ratio; CI: Confidence interval.

DISCUSSION
==========

Currently, diverticulum is no longer considered an obstacle to the success of ERCP cannulation in many studies\[[@B4],[@B9],[@B10]\]. However, PAD with different features may exert different influences on the difficulty of ERCP cannulation\[[@B11],[@B12]\]. Using the Li-Tanaka classification, we observed differences in the difficult cannulation rate and success rate of cannulation among the four types of PAD. The difficult cannulation rate in the type I PAD patients reached 23.08%, but the success rate of cannulation (90.8%) was significantly lower in this type than in types II, III, and IV. Notably, the successful cannulation rate of type II PAD patients was highest (99.4%). Compared to the non-PAD group, the PAD group showed no significant difference in the difficult cannulation rate (*P* = 0.21), but the difficult cannulation rate of patients in the type I PAD group was higher than that of patients in the non-PAD group. The reason is that type I PAD accounts for the lowest percentage (6.7%) among the four types; therefore, it does not affect the difficult cannulation rate of the entire PAD group. The cannulation success rate of the entire PAD group was higher than that of the non-PAD group (*P* = 0.037), but it was lower in the type I PAD group than in the non-PAD group (*P* \< 0.001) and higher in the type II PAD group (*P* = 0.01). No significant difference was observed between the type III and IV PAD groups and the non-PAD group. The Li-Tanaka classification can be used to evaluate the cannulation success rate of different types of PAD compared to non-PAD. Therefore, it has good clinical significance for ERCP cannulation.

In 1998, Lobo et al\[[@B5]\] investigated 100 (8.26%) PAD cases among a total of 1211 cases and found that the cannulation failure rate in the IDP group was higher than that in the JPD group. Similar results were observed for the Lobo classification in our study. IDP in the Lobo classification is equivalent to type I PAD in the Li-Tanaka classification. The difference is that after further subdividing JPD into types II, III, and IV, we found that the success rate was significantly increased only in type II PAD rather than types III and IV PAD compared to non-PAD. In 2006, Boix et al\[[@B2]\] analyzed 131 (32.75%) of 400 PAD patients and found that diverticula did not increase the difficulty of ERCP cannulation. Boix et al\[[@B2]\] proposed a new PAD classification system, but only the proportion of each type was listed, and the influence of the PAD type on cannulation was not examined. Katsinelos et al\[[@B13]\] analyzed 107 PAD cases using this classification method and found no significant difference in the success rates among the three PAD types. Using the Boix classification, in our study, the cannulation success rate in the type II PAD group was higher than that in the non-PAD group. However, it cannot reflect the low success rate of cannulation in IDP. The potential reason is that type I PAD of the Boix classification includes the IDP type and part of the JPD type. As a result, the low successful cannulation rates of IDP were masked.

Does the distance between the diverticulum and papilla affect ERCP cannulation? Some studies have found that when the papilla is located in the diverticulum or is less than 1 cm from the margin of the diverticulum, the diverticulum will cause partial or complete loss of the papillary sphincter\[[@B14]-[@B16]\], which makes it relatively easy for the guidewire to pass through. However, the main reason that the diverticulum increases the difficulty of cannulation is due to the following two aspects\[[@B17],[@B18]\]: The blockage of papillary openings by the diverticulum wall, such as in type I PAD, and the axial deviation of the papilla due to diverticulum compression, such as in types II, III, and IV. Therefore, when the diverticulum covers the papilla and causes difficult cannulation, air should be continuously inflated to fill the diverticulum cavity and expose the opening of the papilla. Moreover, having the diverticulum close to the papilla is beneficial for the success of cannulation. Thus, for cases of types II, III, and IV PAD, attention should be paid to the adjustment of the axial direction. If necessary, specific methods such as double-wire, precut, and pancreatic duct stent placement should be used for cannulation\[[@B19]-[@B22]\]. Cappell et al\[[@B23]\] reported a case in which the diverticulum caused the papilla to be skewed, which led to difficulty in cannulation. Tissue clips were used between the papilla and the intestinal wall, which corrected the direction of the papillary opening, resulting in successful cannulation. Kim et al\[[@B24]\] reported successful cannulation using biopsy forceps to correct the direction of the papillary opening. The major papilla of type II PAD is located in the margin of the diverticulum (\< 1 cm), and a variety of methods are available to correct the axial direction. These may be the main reasons for the high cannulation success rate in type II PAD according to the Li-Tanaka classification. In addition, 655 (67.7%) of the 967 PAD patients were type II patients; therefore, the overall success rate of cannulation in the PAD group was also higher than that in the non-PAD group.

For the Li-Tanaka classification, the EST rate (75.38%) of type I PAD was lowest, and the EPBD and EST with large balloon dilation (ESLBD) rates were approximately 43.1% and 41.5%, respectively. Some studies\[[@B25]-[@B27]\] showed that a small EST followed by EPBD and EPBD alone are both safe and effective methods for PAD patients with cholelithiasis. These techniques do not increase the incidence of adverse events regardless of the PAD subtype. Kim et al\[[@B28]\] found no significant difference between EPBD and EST. Vaira et al\[[@B29]\] found that EST was a safe method in both the PAD and non-PAD groups but that the success rate of EST in the PAD group was lower than that in the non-PAD group. In our study, no significant difference in complications was found among the different PAD types for the 967 PAD cases. Perforation was noted at 72 h after ERCP in one patient with type I PAD, and fully covered self-expandable metal stents were placed. However, the condition could not be improved until surgery was performed. Another case of ERCP-related perforation was found in a type II PAD patient after 24 h; the patient was cured after double biliary stents and one pancreatic duct stent were placed. Because the diameter of type I PAD is larger than that of the other three types and the incision ranges of types I, II, and IV are relatively small, the length and direction of the incision should be strictly controlled to avoid serious adverse events such as perforation\[[@B30]\]. While types III and IVb PADs involve a larger distance between the papilla and diverticulum, the ERCP procedures are similar to those used for non-PAD cases. Some studies have suggested that needle-knife precut fistulotomy is an effective and safe method for difficult cannulation in PAD cases\[[@B19]\]. In addition, most papillae are tilted outwards, which does not increase the risk of EST-related complications\[[@B31]-[@B33]\]. Some studies\[[@B34],[@B35]\] have reported that difficult cannulation is a risk factor for PEP. Although type I PAD exhibited the highest rate of difficult cannulation, the incidence of PEP was not significantly different for this group, and PAD is likely a protective factor against PEP. At present, there is no clear theory to explain this phenomenon, which may be due to the existence of PAD resulting in asymmetric relaxation of the sphincter of Oddi. Therefore, cannulation, EPBD, mechanical lithotripsy, and other ERCP procedures have little impact on the pancreatic sphincter.

The proportion of patients with indications for ERCP including acute cholangitis (11.2% *vs* 17.7%) and common bile duct stones (71.1% *vs* 85.1%) in the non-PAD group was lower than that of the patients in PAD group. This finding may be related to PAD leading to partial loss of sphincter of Oddi muscle function and an increase in bile duct reflux. The sphincter of Oddi in type I PAD patients may be completely absent after repeated ERCP. In addition, the papilla is located in the diverticulum, which is more likely to cause Lemmel syndrome. Therefore, if acute cholangitis or choledocholithiasis recurs frequently after ERCP is performed more than twice in type I PAD patients, choledochojejunostomy should be considered to reduce the related complications caused by regurgitation. Of course, these findings and recom-mendations require further clinical validation.

Although our study had a much larger sample size than other published studies, some limitations should be noted. First, some PAD patients with biliary and pancreatic diseases could not be included in the study because they chose to undergo surgery rather than receive endoscopic treatment. Second, this study was a retrospective study, and some patients were followed for a short period of time; therefore, comparisons of long-term follow-up data for various types of PAD were not performed.

In conclusion, the Li-Tanaka PAD classification method has obvious clinical significance for ERCP cannulation and is helpful for evaluating difficult and successful cannulation for different types of PAD.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Currently, periampullary diverticulum (PAD) is no longer considered an obstacle to the success of ERCP cannulation in many studies. Different types of PAD may differentially affect the difficulty and success of endoscopic retrograde cholangiopancreatography (ERCP) cannulation; however, the clinical significance of the two existing PAD classifications for cannulation is limited.

Research motivation
-------------------

In clinical practice, we found that the effect of PAD on ERCP cannulation was related to the characteristics of the diverticulum. A new PAD classification (Li-Tanaka classification) was proposed, and a retrospective study was conducted to evaluate its clinical guidance value for ERCP cannulation.

Research objectives
-------------------

The objective of this study was to verify the clinical value of our newly proposed PAD classification.

Research methods
----------------

A novel PAD classification (Li-Tanaka classification) was proposed at our center. All PAD patients with native papillae who underwent ERCP from January 2012 to December 2017 were classified according to three classification systems, and the effects of various types of PAD on ERCP cannulation were compared.

Research results
----------------

Unlike Lobo and Boix classifications, Li-Tanaka classification, which is based on the number of PADs and their anatomical relationship with the major papilla, showed different types of PAD with distinguishing difficulty and success rates of ERCP cannulation. In the Li-Tanaka classification, type I PAD patients exhibited the highest difficult cannulation rate, and types II and IV patients had the highest cannulation success rates. In a multivariable-adjusted logistic model, the overall successful cannulation rate in PAD patients was higher than that in non-PAD patients. In addition, compared to the non-PAD group, the difficulty of cannulation in the type I PAD group according to the Li-Tanaka classification was greater, and the success rate of cannulation was lower, while it was higher in the type II PAD group.

Research conclusions
--------------------

Among the three PAD classifications, the Li-Tanaka classification has an obvious clinical advantage for ERCP cannulation, and it is helpful for evaluating potentially difficult and successful cannulation cases among different types of PAD patients.

Research perspectives
---------------------

Long-term effects of different types of PAD on biliary diseases after ERCP are worthy studying at the subsequent follow-up. What's more, further prospective studies are needed to determine the clinical guidance value of PAD classification in ERCP cannulation and complications, and what appropriate techniques can be used for different types of PAD with difficult cannulation.
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